Bafna Pharmaceuticals to sell majority stake of Branded Generics Business to Strides Arcolab

21 Jul 2014 Evaluate

Bafna Pharmaceuticals has entered into a definitive agreement for the sale of majority stake in its India Branded Generics Business to Strides Arcolab. Pursuant to the transaction, Bafna will transfer entire India Branded Generics Business as a going concern on a slump sale basis to Strides and will receive a cash consideration of Rs 48.10 crore and 26% equity in a SPV, where Strides will hold 74%. Under the proposed transaction, Bafna will continue to manufacture and supply the products from its existing manufacturing facilities for a period of five years.

The transaction has been approved by the board and is subject to the approval of shareholders and customary closing conditions. The transaction is expected to close by end of September 2014. KPMG Corporate Finance acted as an exclusive financial advisor and Desai & Diwanji acted as legal advisor to Bafna Pharmaceuticals for this transaction.

India Branded Generics Business of Bafna is engaged in sales and marketing of branded pharmaceuticals products in niche therapeutic segments of Haematinic, Women healthcare, Pediatric care in India and includes the flagship brand ‘Raricap’ and 7 other brands. The Business has presence in 17 states in India with a field force of about 400 people and had revenue of INR 246 million for the financial year ended March 31, 2014.

Bafna Pharma Share Price

88.44 3.69 (4.35%)
23-Apr-2024 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.